MitraClip®: Two Weeks after Implantation

Juliëtte F Velu1, Hans H de Boer2, Berto J Bouma1

  • 1Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.

Insights

A patient with severe mitral regurgitation (MR) underwent successful MitraClip repair, reducing MR significantly. However, the patient later died from pneumosepsis, with histology revealing inflammation and early tissue coverage on the device.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomaterials Science

Background:

  • Severe symptomatic mitral regurgitation (MR) poses significant clinical challenges.
  • Percutaneous mitral valve repair using the MitraClip device offers a less invasive treatment option for MR.
  • Understanding the long-term tissue response to implanted devices is crucial for patient outcomes.

Observation:

  • A 73-year-old male patient with severe MR underwent successful MitraClip repair, reducing MR from grade IV to grade I.
  • The patient experienced a fatal outcome (pneumosepsis) 14 days post-procedure.
  • Histological examination of the MitraClip mesh revealed a chronic inflammatory reaction with multinucleated giant cells.

Findings:

  • The MitraClip device demonstrated effectiveness in reducing mitral regurgitation.
  • Histology showed a significant foreign body reaction, characterized by multinucleated giant cells.
  • Early signs of tissue coverage (myofibroblast presence) on the MitraClip mesh were observed.

Implications:

  • While MitraClip effectively treats MR, potential inflammatory responses and early tissue coverage warrant further investigation.
  • The findings highlight the importance of monitoring for complications such as infection post-procedure.
  • Further research is needed to understand the long-term biological interactions between the MitraClip device and cardiac tissue.

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
In Vitro Fertilization01:24

In Vitro Fertilization

In vitro fertilization (IVF) is a form of assisted reproductive technology where an egg is fertilized with sperm in a controlled laboratory environment before transferring the resulting embryo into the uterus. This process is designed to help individuals and couples experiencing difficulties conceiving.
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...